Pegah Rasoulian

Dr. Pegah Rasoulian

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in BMC Neurology
Verified
Journal Article
Open access
PDF file
PRPegah Rasoulian
Pegah Rasoulian
EKEmadoddin Kazemi
Emadoddin Kazemi
TTTina Taherkhani
Tina Taherkhani
HNHoda Niavarani
Hoda Niavarani
NTNikaein Zabeti Targhi
Nikaein Zabeti Targhi
KDKhashayar Danandeh
Khashayar Danandeh
Meningitis and encephalitis are significant contributors to morbidity and mortality worldwide. This study aimed to provide a comprehensive overview of the trends and epidemiology of these diseases in Iran from 1990 to 2021. Data from the Global Burden of Disease (GBD) study were utilized to assess the epidemiology and burden of meningitis and encephalitis in Iran. This study compared these findings with those of global and Middle East and North Africa (MENA) countries. Age-standardized rates for incidence, prevalence, and disability-adjusted life years (DALYs) were calculated, and trends over time were analyzed. This study revealed a substantial reduction in the burden of meningitis over the observed period, with a -85.81% decrease in age-standardized DALYs rates from 1990 to 2021. Encephalitis rates also decreased, though to a lesser extent. Significant disparities in disease burden were observed across different sexes and age groups, with higher rates among males and in the < 5 years and ≥ 90 years’ age groups. Provincial disparities were also noted, with the highest age-standardized DALYs rates for meningitis in provinces such as Sistan and Baluchistan, Kohgiluyeh and Boyer-Ahmad, and Hamadan. This study highlights the progress made in reducing the burden of meningitis and encephalitis in Iran over the past three decades. However, the observed disparities across sexes, age groups, and provinces emphasize the need for continued efforts in surveillance, prevention, and treatment to further alleviate the impact of these diseases.

29 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MBMehrdad Behboodi
Mehrdad Behboodi
MMMaryam Moghbel
Maryam Moghbel
AZAnahita Zoghi
Anahita Zoghi
ZBZahra Bahrevar
Zahra Bahrevar
MRMahrooz Roozbeh
Mahrooz Roozbeh
PRPegah Rasoulian
Pegah Rasoulian
The intersection of COVID-19 and neurological complications has highlighted post-COVID anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, a severe autoimmune disorder mediated by antibodies targeting NMDA receptors. This systematic review and institutional case series aimed to synthesize existing literature and present eight new cases from Tehran, Iran, to clarify the pathophysiology, prevalence, clinical manifestations, diagnostic challenges, and therapeutic strategies of this emerging condition. A total of 23 adult patients were analyzed, including 15 cases from the literature and 8 new institutional cases. The mean age was 35.6 years, with a female predominance (60.9%). SARS-CoV-2 infection was confirmed in 91.3% of patients by RT-PCR. The median latency from COVID-19 diagnosis to encephalitis onset was 10 days, with 91.3% occurring within the first month. Neuropsychiatric manifestations were nearly universal (91.3%), including psychosis/hallucinations (56.5%), behavioral or cognitive disturbances (52.2%), seizures (52.2%), movement disorders (34.8%), and altered consciousness (43.5%). MRI revealed abnormalities in 59.1% (most frequently hippocampal involvement), and EEG abnormalities were present in 76.2%, with diffuse slowing, epileptiform activity, and delta brush patterns. Anti-NMDAR antibodies were detected in CSF or serum in 60.9% of cases, with pleocytosis in 34.8%. First-line immunotherapies included intravenous methylprednisolone (87.0%), intravenous immunoglobulin (56.5%), and plasmapheresis (34.8%), while rituximab was used in 30.4% as second-line therapy. At a median 3-month follow-up, 52.2% achieved full recovery, 39.1% partial recovery, and 8.7% died. This study underscores the temporal association between COVID-19 and anti-NMDAR encephalitis, with a consistent clinical phenotype and treatment response resembling classical cases. Early recognition, timely antibody testing, and initiation of immunotherapy are critical to improving outcomes. Larger, prospective studies are warranted to confirm causality, refine diagnostic algorithms, and optimize management strategies.

28 January 2026 in Journal of Autism and Developmental Disorders
Verified
Journal Article
Closed access
PDF file
TPTanin adl parvar
Tanin adl parvar
KKKeyvan Karimi
Keyvan Karimi
PRPegah Rasoulian
Pegah Rasoulian
SDSina Dolatshahi
Sina Dolatshahi
SASara Asgarian
Sara Asgarian
MMMohammad Ali Mansournia
Mohammad Ali Mansournia